The Tolerability of the Vaccine against P. aeruginosa in Children with Cystic Fibrosis and Congenital Lung Development
Chronic Pseudomonas aeruginosa infection is the most common cause of the failure in treatment and of adverse outcomes among children with congenital malformation of the lung (CML) and cystic fibrosis (CF). Purpose: To evaluatae the safety of anti Pseudomonas aeruginosa vaccine in children with conge...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Numikom LLC
2016-04-01
|
| Series: | Эпидемиология и вакцинопрофилактика |
| Subjects: | |
| Online Access: | https://www.epidemvac.ru/jour/article/view/149 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849250297828868096 |
|---|---|
| author | D. A. Blagovidov M. P. Kostinov O. I. Simonova A. D. Shmit'ko N. I. Burkina M. K. Shahnazaryan |
| author_facet | D. A. Blagovidov M. P. Kostinov O. I. Simonova A. D. Shmit'ko N. I. Burkina M. K. Shahnazaryan |
| author_sort | D. A. Blagovidov |
| collection | DOAJ |
| description | Chronic Pseudomonas aeruginosa infection is the most common cause of the failure in treatment and of adverse outcomes among children with congenital malformation of the lung (CML) and cystic fibrosis (CF). Purpose: To evaluatae the safety of anti Pseudomonas aeruginosa vaccine in children with congenital malformation of the lung and cystic fibrosis. Material and methods: 81 hospitalized children aged 5 to 17 with congenital malformation of the lung and cystic fibrosis participated in the research. 47 patients not experiencing exacerbation during basic therapy were vaccinated with anti Pseudomonas aeruginosa vaccine Pseudovac that consists of structural and extra-cellular antigens of the 8 immunotypes of Pseudomonas aeruginosa. The control group included 34 children who were not vaccinated, and had P. aeruginosa acquisition or infection. All the patients were under observation for the period of one year. Results: Pain in the injection site was registered in 74.5% and 76.6% of cases after the first and the second administration respectively. Further injections (3rd, 4th and 5th) of the vaccine caused much less local pain. In the majority of cases pain was mild and disappeared without medication within 24 hours. Redness in the injection site was registered in 29.8% of cases after the second administration of the vaccine. After further injections it was significantly less common. Local swelling in the injection site of not more than 25 mm after the first injection of the vaccine was registered in 57% of the cases, and in 100% of the cases after the second injection. It lasted less than 24 hours. Among vaccinated patients fever up to 37.5 degrees Celsius was registered in 23,4% of the cases. And up to 38.5 degrees in 4,3% of the cases. The reaction was observed within two hours after the injection and appeared regardless of the number of administrations lasting no longer than 24 hours. There appeared other single general reactions such as headache, dizziness or dry cough lasting up to 6 hours. |
| format | Article |
| id | doaj-art-3fd7ba53ae854b15b251fcfaeae7ba6e |
| institution | Kabale University |
| issn | 2073-3046 2619-0494 |
| language | Russian |
| publishDate | 2016-04-01 |
| publisher | Numikom LLC |
| record_format | Article |
| series | Эпидемиология и вакцинопрофилактика |
| spelling | doaj-art-3fd7ba53ae854b15b251fcfaeae7ba6e2025-08-20T03:57:18ZrusNumikom LLCЭпидемиология и вакцинопрофилактика2073-30462619-04942016-04-01152556610.31631/2073-3046-2016-15-2-55-66148The Tolerability of the Vaccine against P. aeruginosa in Children with Cystic Fibrosis and Congenital Lung DevelopmentD. A. Blagovidov0M. P. Kostinov1O. I. Simonova2A. D. Shmit'ko3N. I. Burkina4M. K. Shahnazaryan5I.I. Mechnikov Research Institute of Vaccines and Sera of Russian Academy of SciencesI.I. Mechnikov Research Institute of Vaccines and Sera of Russian Academy of SciencesFederal State Budgetary Institution «Scientific Center of Children's Health»I.I. Mechnikov Research Institute of Vaccines and Sera of Russian Academy of SciencesFederal State Budgetary Institution «Scientific Center of Children's Health»Federal State Budgetary Institution «Scientific Center of Children's Health»Chronic Pseudomonas aeruginosa infection is the most common cause of the failure in treatment and of adverse outcomes among children with congenital malformation of the lung (CML) and cystic fibrosis (CF). Purpose: To evaluatae the safety of anti Pseudomonas aeruginosa vaccine in children with congenital malformation of the lung and cystic fibrosis. Material and methods: 81 hospitalized children aged 5 to 17 with congenital malformation of the lung and cystic fibrosis participated in the research. 47 patients not experiencing exacerbation during basic therapy were vaccinated with anti Pseudomonas aeruginosa vaccine Pseudovac that consists of structural and extra-cellular antigens of the 8 immunotypes of Pseudomonas aeruginosa. The control group included 34 children who were not vaccinated, and had P. aeruginosa acquisition or infection. All the patients were under observation for the period of one year. Results: Pain in the injection site was registered in 74.5% and 76.6% of cases after the first and the second administration respectively. Further injections (3rd, 4th and 5th) of the vaccine caused much less local pain. In the majority of cases pain was mild and disappeared without medication within 24 hours. Redness in the injection site was registered in 29.8% of cases after the second administration of the vaccine. After further injections it was significantly less common. Local swelling in the injection site of not more than 25 mm after the first injection of the vaccine was registered in 57% of the cases, and in 100% of the cases after the second injection. It lasted less than 24 hours. Among vaccinated patients fever up to 37.5 degrees Celsius was registered in 23,4% of the cases. And up to 38.5 degrees in 4,3% of the cases. The reaction was observed within two hours after the injection and appeared regardless of the number of administrations lasting no longer than 24 hours. There appeared other single general reactions such as headache, dizziness or dry cough lasting up to 6 hours.https://www.epidemvac.ru/jour/article/view/149детимуковисцидозхронические заболевания легкихсинегнойная инфекциявакцинациябезопасностьchildrencystic fibrosischronic lung diseasepseudomonas infectionvaccinationsafety |
| spellingShingle | D. A. Blagovidov M. P. Kostinov O. I. Simonova A. D. Shmit'ko N. I. Burkina M. K. Shahnazaryan The Tolerability of the Vaccine against P. aeruginosa in Children with Cystic Fibrosis and Congenital Lung Development Эпидемиология и вакцинопрофилактика дети муковисцидоз хронические заболевания легких синегнойная инфекция вакцинация безопасность children cystic fibrosis chronic lung disease pseudomonas infection vaccination safety |
| title | The Tolerability of the Vaccine against P. aeruginosa in Children with Cystic Fibrosis and Congenital Lung Development |
| title_full | The Tolerability of the Vaccine against P. aeruginosa in Children with Cystic Fibrosis and Congenital Lung Development |
| title_fullStr | The Tolerability of the Vaccine against P. aeruginosa in Children with Cystic Fibrosis and Congenital Lung Development |
| title_full_unstemmed | The Tolerability of the Vaccine against P. aeruginosa in Children with Cystic Fibrosis and Congenital Lung Development |
| title_short | The Tolerability of the Vaccine against P. aeruginosa in Children with Cystic Fibrosis and Congenital Lung Development |
| title_sort | tolerability of the vaccine against p aeruginosa in children with cystic fibrosis and congenital lung development |
| topic | дети муковисцидоз хронические заболевания легких синегнойная инфекция вакцинация безопасность children cystic fibrosis chronic lung disease pseudomonas infection vaccination safety |
| url | https://www.epidemvac.ru/jour/article/view/149 |
| work_keys_str_mv | AT dablagovidov thetolerabilityofthevaccineagainstpaeruginosainchildrenwithcysticfibrosisandcongenitallungdevelopment AT mpkostinov thetolerabilityofthevaccineagainstpaeruginosainchildrenwithcysticfibrosisandcongenitallungdevelopment AT oisimonova thetolerabilityofthevaccineagainstpaeruginosainchildrenwithcysticfibrosisandcongenitallungdevelopment AT adshmitko thetolerabilityofthevaccineagainstpaeruginosainchildrenwithcysticfibrosisandcongenitallungdevelopment AT niburkina thetolerabilityofthevaccineagainstpaeruginosainchildrenwithcysticfibrosisandcongenitallungdevelopment AT mkshahnazaryan thetolerabilityofthevaccineagainstpaeruginosainchildrenwithcysticfibrosisandcongenitallungdevelopment AT dablagovidov tolerabilityofthevaccineagainstpaeruginosainchildrenwithcysticfibrosisandcongenitallungdevelopment AT mpkostinov tolerabilityofthevaccineagainstpaeruginosainchildrenwithcysticfibrosisandcongenitallungdevelopment AT oisimonova tolerabilityofthevaccineagainstpaeruginosainchildrenwithcysticfibrosisandcongenitallungdevelopment AT adshmitko tolerabilityofthevaccineagainstpaeruginosainchildrenwithcysticfibrosisandcongenitallungdevelopment AT niburkina tolerabilityofthevaccineagainstpaeruginosainchildrenwithcysticfibrosisandcongenitallungdevelopment AT mkshahnazaryan tolerabilityofthevaccineagainstpaeruginosainchildrenwithcysticfibrosisandcongenitallungdevelopment |